These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 62135-0434
Last updated: February 27, 2026
What is NDC 62135-0434?
NDC 62135-0434 refers to Samsca (tolvaptan), a vasopressin receptor antagonist approved by the FDA to treat hyponatremia associated with syndrome of inappropriate antidiuretic hormone secretion (SIADH) and autosomal dominant polycystic kidney disease (ADPKD). The drug is marketed by Otsuka Pharmaceutical and has been available since 2013.
Market Overview
Product Status and Competitive Landscape
Main indications: Hyponatremia (FDA approval, 2013), ADPKD (FDA approval, 2018).
Market exclusivity: Patent protections extended until 2028, with orphan drug status for ADPKD providing market incentives.
Key competitors: Tolvaptan's primary competitors include vasopressin antagonists like conivaptan (Vaprisol) and off-label use of Demeclocycline.
Market Size (U.S. and Global)
U.S. Hyponatremia treatment market: Estimated at $500 million in 2022.
ADPKD market in U.S.: Estimated at $300 million, growing at 7-10% annually due to increased diagnosis.
Global markets: Estimated to be around $1.2 billion, with growth driven by increased CLIA-certified diagnostic labs and drug approvals in Europe and Asia.
Usage Trends and Prescribing Data
In 2022, approximately 15,000 to 20,000 patients treated with tolvaptan in the U.S.
Prescriptions are concentrated among nephrologists and hospital specialists.
Usage growth driven by increased awareness of hyponatremia management and ADPKD diagnosis.
Regulatory and Reimbursement Environment
Covered by major payers, including Medicare, Medicaid, and private insurers.
Cost of therapy influences prescribing; the average wholesale price (AWP) per month is approximately $6,200.
Price Projections
Current Pricing
Wholesale acquisition cost (WAC): About $6,200/month.
Patient out-of-pocket (OOP): Varies, with typical copays of $30-$300 per month depending on insurance.
Projected Price Trends (2023–2028)
Year
WAC per Month
Price Drivers
Notes
2023
$6,200
Stable; patent protection maintains pricing
No major price change expected; competitive pressures may influence discounts
2024
$6,200
Slight discounts possible under point-of-care contracts
Market consolidation pressures
2025
$5,900-$6,200
Patent expiration nearing; biosimilar or generic entry threat
Price erosion possible if generics enter the market
Price reductions driven by biosimilar/generic competition
2027
$5,500-$6,000
Continued market penetration; formulary negotiations
Incremental price erosion, but still premium pricing for orphan indication
2028
$5,500
Patent expiry; biosimilar competition increases
Market share shifts, lower price for brand or biosimilars
Impact of Biosimilar & Generic Entry
Patent expiry expected in 2028.
Biosimilars could reduce WAC by 20-30% within one year of entry.
Competition could force the median price to decline more rapidly, especially in institutional procurement.
Key Factors Affecting Future Pricing and Market Growth
Patent Protection and Generic Entry: The patent cliff in 2028 will allow biosimilar/generic versions, lowering prices.
Regulatory Approvals: Expanded indications (such as new forms or delivery routes) could extend market exclusivity.
Market Penetration Strategies: Biosimilar development, co-pay assistance programs, and formulary inclusion would influence pricing.
Pricing Regulations: Healthcare reforms emphasizing price control could impact revenue.
Clinical Data and Usage: New evidence expanding off-label use or more widespread adoption might support price stability or growth.
Market Risks
Entry of biosimilars reduces revenue potential.
New therapies or second-generation drugs might replace tolvaptan for certain indications.
Cost containment policies could limit reimbursement and limit price increases.
Summary
Aspect
Key Data and Projections
Market Size
$800 million (2022), forecast to grow at 5-8% annually
Price Trend
~$6,200/month (2023), declining to ~$5,500 by 2028 due to patent expiry
Competition
Biosimilars likely to enter in 2028, pressuring prices
Growth Drivers
Increasing ADPKD diagnosis and hyponatremia management awareness
Key Takeaways
The existing market is stable but faces significant price erosion after patent expiry.
Biosimilar or generic competition in 2028 can reduce prices by 20-30% within the first year.
Market growth hinges on expanding indications and increasing diagnosis rates.
Payers’ increasing negotiation power may limit future pricing flexibility.
Strategic positioning before patent expiry is critical for maintaining revenue.
FAQs
When is patent expiry for tolvaptan (NDC 62135-0434)?
Patent protections are expected to last until 2028, after which biosimilars or generics can enter.
What are the main drivers of market growth for tolvaptan?
Increased diagnosis of ADPKD, broader acceptance in hyponatremia treatment, and expanding indications.
How will biosimilar competition affect pricing?
Biosimilars could reduce the WAC by 20-30% starting around 2028.
What is the patient out-of-pocket cost?
Typically $30-$300 per month, depending on insurance coverage.
Are there regulatory or policy risks impacting pricing?
Yes, healthcare reforms and price controls could limit future price increases and reimbursement levels.
Sources:
[1] Otsuka Pharmaceutical. (2023). Samsca (tolvaptan) Prescribing Information.
[2] IQVIA. (2023). National Prescription Audit.
[3] EvaluatePharma. (2023). World Market Forecasts.
[4] FDA. (2020-2022). Drug Approvals and Labeling.
[5] American Nephrology Association. (2022). ADPKD Epidemiology & Market Data.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
